{"entity":{"id":"surface-oncology","kind":"company","name":"Surface Oncology","aka":["Surface Oncology, Inc."],"tldr":"Surface Oncology made antibodies meant to break down the defences tumours build around themselves against the immune system. Coherus BioSciences bought it in 2023.","summary":"Surface Oncology was a clinical-stage immuno-oncology company developing immunotherapies that target the tumour microenvironment. Coherus BioSciences closed its acquisition on 8 September 2023, issuing 0.1960 Coherus shares per Surface share. The assets that came from Surface were casdozokitug (SRF388), an IL-27-targeted antibody then in Phase 2 trials in lung cancer and liver cancer, and SRF114, an ADCC-enhanced CCR8-targeted antibody in a Phase 1/2 study in advanced solid tumours. Atlas Venture lists Surface as developing antibodies to break through the tumour microenvironment, sold to Coherus in 2023.","asOf":"2026-11-04","links":[{"label":"Coherus completes Surface Oncology acquisition (SEC exhibit, 8 September 2023)","url":"https://www.sec.gov/Archives/edgar/data/1512762/000155837023015582/chrs-20230908xex99d1.htm"},{"label":"Atlas Venture portfolio entry","url":"https://atlasventure.com/portfolio/"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["monoclonal-antibody"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["OnCo has no target record for IL-27 or CCR8, so no targets are set. The Coherus release also lists CHS-006 (TIGIT) but does not say it came from Surface.","Casdozokitug and SRF114 are not drug records in OnCo; as Coherus now owns them, any product record belongs to Coherus.","Founding year not stated in the sources read. HQ from the SEC EDGAR business address."],"hq":"Cambridge, MA","country":"US","companyType":"biotech","stage":"acquired","investors":["atlas-venture"],"funding":[],"acquiredBy":"coherus"},"route":"/companies/surface-oncology/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"company":[{"id":"atlas-venture","kind":"company","name":"Atlas Venture","route":"/companies/atlas-venture/"},{"id":"coherus","kind":"company","name":"Coherus BioSciences","route":"/companies/coherus/"}]}}